Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 640 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Transfusion Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Blood Warming in Preterm Infants to Decrease Hypothermia

NCT05170633
View directory record Official record
Conditions
Preterm Birth, Blood Transfusion Complication, Hypothermia
Interventions
Ranger blood warmer (3M Healthcare, Oakdale, Minnesota)
Device
Lead sponsor
University of South Carolina
Other
Eligibility
24 Weeks to 32 Weeks
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 21, 2026, 11:58 PM EDT
Completed No phase listed Observational

Trauma Induced Coagulopathy and Inflammation

NCT03128658
View directory record Official record
Conditions
Trauma Injury, Trauma, Coagulopathy
Interventions
Thromboelastography, Computational model
Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 21, 2026, 11:58 PM EDT
Withdrawn Not applicable Interventional

iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes

NCT03446638
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
FDA-approved drug or combination of drugs, FLAG induction, 7 + 3 induction, Low-dose cytarabine, Supportive care alone, Computational biology simulations software
Drug · Other · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 21, 2026, 11:58 PM EDT
Completed Phase 2 Interventional Results available

Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload

NCT00901199
View directory record Official record
Conditions
Thalassemia, Iron Overload
Interventions
Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO)
Drug
Lead sponsor
Elliott Vichinsky
Other
Eligibility
8 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 21, 2026, 11:58 PM EDT
Completed Not applicable Interventional Results available

Shared-Decision Making for Hydroxyurea

NCT03442114
View directory record Official record
Conditions
Sickle Cell Anemia, Children, Only
Interventions
Hydroxyurea SDM Toolkit, Clinician Pocket Guide
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Month to 5 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Oakland, California • Wilmington, Delaware • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 21, 2026, 11:58 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia

NCT07517133
View directory record Official record
Conditions
Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
Interventions
Mitapivat, Placebo Matching Mitapivat
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
5
States / cities
Palo Alto, California • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 11:58 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Detecting Autologous Transfusion by Measuring Alterations in the Dynamics of Red Blood Cell Maturation and Recycling

NCT02684747
View directory record Official record
Conditions
Blood Transfusion, Autologous, Blood Doping
Interventions
Autologous Transfusion, Control - Normal Saline (Placebo)
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 21, 2026, 11:58 PM EDT
Recruiting Not applicable Interventional

The Use of Karl Storz Curved Fetoscope (11508aak) and Its Straight Version (11506akk) for In-utero Surgery

NCT06425471
View directory record Official record
Conditions
In Utero Procedure Affecting Fetus or Newborn
Interventions
KARL STORZ fetoscope arm
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 21, 2026, 11:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)

NCT00833898
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer
Interventions
Paced respiration as part of PEPRR, PEPRR
Device · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 21, 2026, 11:58 PM EDT
Completed Phase 2 Interventional Results available

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

NCT01358734
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myelogenous Leukemia
Interventions
Azacitidine, Lenalidomide, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
65 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
24
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 21, 2026, 11:58 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of Oral TXA in Reducing Blood Loss and Transfusion in Hip Fractures

NCT02908516
View directory record Official record
Conditions
Hip Fractures, Blood Loss
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 21, 2026, 11:58 PM EDT
Terminated Phase 2 Interventional Results available

Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)

NCT00953771
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Danazol
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 21, 2026, 11:58 PM EDT
Completed Phase 2 Interventional Results available

Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery

NCT00914589
View directory record Official record
Conditions
Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass
Interventions
catridecacog, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
Atlanta, Georgia • Durham, North Carolina • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 21, 2026, 11:58 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

NCT06045689
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Luspatercept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Los Alamitos, California • New Haven, Connecticut • St. Petersburg, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 21, 2026, 11:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alteration of Stool Microbiota in Preterm Infants With Anemia

NCT03554278
View directory record Official record
Conditions
Anemia, Neonatal, Necrotizing Enterocolitis, Dysbiosis
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
7 Days to 30 Days
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 21, 2026, 11:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating Therapy

NCT04171635
View directory record Official record
Conditions
MRI Scans
Interventions
Quantitative Susceptibility Mapping (QSM) Magnetic Resonance Imaging (MRI), R2* Magnetic Resonance Imaging (MRI)
Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
2 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 21, 2026, 11:58 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Off-pump Versus On-pump Coronary Artery Bypass Grafting in Frail Patients

NCT02338947
View directory record Official record
Conditions
Frail Elderly, Coronary Artery Disease
Interventions
Off-pump coronary-artery bypass grafting, On-pump coronary-artery bypass grafting
Other
Lead sponsor
University of Sao Paulo General Hospital
Other
Eligibility
60 Years and older
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 21, 2026, 11:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Home Transfusion for HEME

NCT05509439
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
Home Transfusion Program Components
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 21, 2026, 11:58 PM EDT
Not listed Not applicable Interventional

Effects of Tranexamic Acid on Blood Loss and Transfusion Requirement Following Hip Fracture

NCT02738073
View directory record Official record
Conditions
Hip Fracture
Interventions
Control: Saline, Tranexamic Acid
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Bryn Mawr, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 21, 2026, 11:58 PM EDT
Completed Not applicable Interventional

rhTPO Mobilized Auto Cryo Platelets For GYN Patients Receiving Carboplatin

NCT00038012
View directory record Official record
Conditions
Neoplasms, Gynecologic
Interventions
Thrombopoietin, Platelet-pheresis, Carboplatin
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 21, 2026, 11:58 PM EDT
Active, not recruiting Phase 2 Interventional

A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

NCT06113302
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Luspatercept
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 21, 2026, 11:58 PM EDT
Completed Phase 3 Interventional Results available

Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease

NCT01652872
View directory record Official record
Conditions
Anemia in Chronic Kidney Disease Patients Not on Dialysis
Interventions
Darbepoetin alfa, Placebo
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
243
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 198 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 21, 2026, 11:58 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma

NCT04502472
View directory record Official record
Conditions
Covid-19
Interventions
Convalescent plasma transfusion
Biological
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 21, 2026, 11:58 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)

NCT04770753
View directory record Official record
Conditions
Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
Interventions
Placebo Matching Mitapivat, Mitapivat
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
6
States / cities
La Jolla, California • Palo Alto, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 11:58 PM EDT